Navigation Links
Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Date:2/5/2010

LONDON and PALO ALTO, Calif., Feb. 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that Philip Haworth, Ph.D., chief executive officer, will deliver a corporate overview and business update at the 12th Annual BIO CEO & Investor Conference.  The conference will be held February 8-9, 2010 at the Waldorf-Astoria Hotel in New York City.

Silence's presentation will take place at 11:00 a.m. Eastern on Monday, February 8, 2010.  The corporate update provided by Dr. Haworth will include an overview of the company's recent merger with Intradigm Corporation, as well as details on the company's expanded RNA interference (RNAi) therapeutic platform and pipeline.  

To access a live audio webcast of the presentation, please log on through a link located on the Presentations page of the Investor Relations section of Silence's website at http://www.silence-therapeutics.com/index.php?option=com_content&task=view&id=88&Itemid=88

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ offers safe and effective systemic administration using a library of novel peptide-based biodegradable polycationic polymers.  Additionally, the company has a platform of novel short interfering RNA (siRNA) molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

Silence has built a strong and diverse intellectual property portfolio covering all essential areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences and key siRNA structural and chemical features, as well as specific high-value disease targets.  This portfolio includes an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development operations in Berlin and Palo Alto, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

SOURCE Silence Therapeutics PLC

RELATED LINKS
http://www.intradigm.com

'/>"/>

SOURCE Silence Therapeutics PLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
2. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
3. Silence Therapeutics Patent Update
4. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
5. Organizational Changes at Silence Therapeutics
6. Silence Therapeutics Announces Successful Opposition of Glover Patent
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
10. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
11. The Honorable Tommy G. Thompson Joins the United Therapeutics Corporation Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Elekta is pleased to ... its industry-leading treatment planning software, is available for clinical ... version 5.11 provides significant performance speed enhancements ... up to four times faster than in previous versions ... gold standard Monte Carlo algorithm, ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... screen mobile devices with fingerprint recognition for secure access, voice recognition for hands-free ... few ways consumers are interacting with biometrics technology today. But if they ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):